CLX Investment Company Announces Information on U.S. Infectious Disease Market for Zonda Product Line.

TEMECULA, Calif. -- CLX Investment Company, Inc. (OTCBB:CLXN) today announced that the market for chlamydia and gonorrhea tests in the United States reached 54 million in 2004, which represented a market of almost $220 million. CLX portfolio investment Zonda, Inc. has developed innovative, rapid, self-contained diagnostic devices for the detection of diseases including chlamydia, gonorrhea and other infectious bacteria. E[acute accent]Chlamydia and gonorrhea are sexually transmitted diseases (STDs) caused by bacteria. Both are curable with antibiotic treatments, making early detection particularly important. Chlamydia is one of the most widespread bacterial STDs in the United States. The Centers for Disease Control and Prevention (CDC) estimates that more than 3 million people are infected with Chlamydia each year and has stated that under-reporting is substantial because most people with chlamydia are not aware of their infections and do not seek testing. Gonorrhea is also a very common STD, with 351,852 U.S. cases reported to the CDC in 2002, the most recent year numbers are available. The CDC officially estimates that more than 700,000 persons in the U.S. get new gonorrheal infections each year. E[acute accent]Left undetected and untreated, these common venereal diseases can cause serious and permanent health problems in both men and women, including infertility. E[acute accent]Zonda products are also designed to detect bacteria other than those categorized as STDs. There has been greater attention in recent years on infectious bacteria, such as Strep A, which can cause a number of conditions, from minor infections to life threatening invasive disease. Industry analysts have calculated the U.S. market for Strep A testing to be approximately $74 million. E[acute accent]"A new emphasis on rapid detection can only assist in limiting the spread of infectious disease in the United States, and we look forward to bringing Zonda's over-the-counter and professional point-of-care testing products to this country," stated Tammy D. Dunn, chief executive officer of CLX Investment Company. "These industry numbers clearly indicate how large an opportunity that the U.S. infectious disease testing market is for Zonda, and we expect to add U.S. regulatory approval and distribution to the other worldwide markets where Zonda's products are already being distributed. The goal is for Zonda to have global reach, and CLX is providing the support necessary for Zonda to achieve this goal." E[acute accent]Zonda Inc., a privately held company that specializes in test products that serve the medical diagnostic (IVD), food safety, and sanitation testing markets, is expanding the distribution of its product lines into broader markets around the world. The first product targeted for accelerated marketing and distribution efforts is an innovative, rapid, self-contained diagnostic device for the detection of Chlamydia, which carries a CE mark for both professional point-of-care and over-the-counter use. The device, which is marketed under the HandiLab-C name, is superior to its competition due to its comparable accuracy (compared directly to PCR testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness. Other similar products for the detection of gonorrhea, yeast and Strep A carry CE marks for professional point-of-care use.

E[acute accent]About the Company

E[acute accent]CLX Investment Company (www.clxinvestments.com) has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders. E[acute accent]CLX has acquired a 49% interest in eStrategy Solutions, Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. The Company has made an investment in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. CLX holds a 20% equity interest in Zonda, Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets.

E[acute accent]All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.